Economist Radio
Economist Radio
Mar 29, 2021
The Jab: How will science benefit?
Play • 40 min

The concerted and rapid efforts to counter covid-19 have turbo-charged scientific progress. How can this new knowledge be applied to treat future threats to human health? 


Gregg Glenn, head of research and development at Novavax on why that vaccine is effective against variants. 


Alok Jha, The Economist's science correspondent, hosts with our health policy editor, Natasha Loder. Oliver Morton, briefings editor, Cuba correspondent Roseanne Lake and James Fransham from our data team join them.


For full access to The Economist’s print, digital and audio editions subscribe at Sign up for our new weekly science and data newsletters at and  


See for privacy and opt-out information.

More episodes
Clear search
Close search
Google apps
Main menu